Structure-Affinity relationships of novel σ2R/TMEM97 ligands

Walby, Grant D.; Gu, Qi; Yang, Hongfen; Martin, Stephen F.

doi:10.1016/j.bioorg.2024.107191

Cited by 1 publication

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a final example, Walby et al [25] very recently explored the structure-activity relationships of novel benzoxazocine, benzomorphan, and methanobenzazepine ligands for S2R activity. Computational docking studies again supported electrostatic interactions (H-bonding with Asp29 and cation-π with Tyr150) with the binding pocket of the S2R (Figure 2).…”

Section: Figure 1: Bovine Sigma-2 Receptor Bound To Roluperidonementioning

confidence: 99%

See 1 more Smart Citation

Recent Developments in Sigma-2 Receptor Compounds for Pain

Raffa,

Pergolizzi

2024

Cureus

View full text Add to dashboard Cite

After years of enigmatic pharmacology, non-selective ligands, and uncertain clinical application, sigma receptors have emerged as interesting therapeutic drug discovery-development targets. Two subtypes of sigma receptors have now been cloned, sigma-1 receptor (S1R) and sigma-2 receptor (S2R), and there has been much complementary and converging information from advances in molecular biology, computer modeling, virtual screening, and in vitro and in vivo testing. One of several evolving areas of therapeutic potential is for the treatment of pain. In particular, there is accumulating recent evidence from preclinical models that the demonstrated positive effects of S2R compounds in these models suggest possible positive implications for clinical effectiveness against pains that have a neuropathic component. Such pain conditions have imperfect therapeutic options currently. The addition of new drugs to the now available armamentarium would represent a very significant advance for the large number of patients who suffer from these types of intractable pain. Further research is needed to identify and characterize compounds that have not only good in vitro activity but also the characteristics needed to enter clinical trials. Here, we summarize some of the recent reports of the analgesic activity of S2R compounds.

show abstract

Section: Figure 1: Bovine Sigma-2 Receptor Bound To Roluperidonementioning

confidence: 99%

“…FIGURE 2: Model of binding pocket of S2R showing important residues for bindingImage from Walby et al with permission[25] …”

mentioning

confidence: 99%